CHANDRASEKHAR CHANDA

CHANDRASEKHAR CHANDA

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA
ASAngshuman Sarkar
Angshuman Sarkar
Srinivas SistlaSrinivas Sistla
Srinivas Sistla
DCDibakar Chakrabarty
Dibakar Chakrabarty

1 January 2016 in Archives of Biochemistry and Biophysics
Verified
Journal Article
Closed access
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA
ASAngshuman Sarkar
Angshuman Sarkar
DCDibakar Chakrabarty
Dibakar Chakrabarty

14 June 2011 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA
DCDibakar Chakrabarty
Dibakar Chakrabarty

7 March 2024 in Journal of Biosciences
Verified
Journal Article
Closed access
PDF file
ARAnanda Murali Rayapati
Ananda Murali Rayapati
BVBhadramurthy Vemulapati
Bhadramurthy Vemulapati
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA

27 December 2023 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
LBLekhana Bandi
Lekhana Bandi
NLNaga Shivani Lakshmisetty
Naga Shivani Lakshmisetty
KAKeerthana Ankireddy
Keerthana Ankireddy
LPLeela Lakshmi Vaishnavi Pulipati
Leela Lakshmi Vaishnavi Pulipati
ABAsritha Lakshmi Bontu
Asritha Lakshmi Bontu
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA
Lekhana Bandi1, Naga Shivani Lakshmisetty1, Keerthana Ankireddy1, Leela Lakshmi Vaishnavi Pulipati1, Asritha Lakshmi Bontu1, Ranganadha Reddy Aluru2 and Chandrasekhar Chanda1 Author informationPDFCitations Corresponding author. Correspondence: Dr. Chandrasekhar Chanda Department of Biotechnology, Koneru Lakshmaiah Education Foundation, Vaddeswaram-522502, Andhra Pradesh, INDIA. Email: chandrasekharchanda02@gmail.com Author Notes Received September 21, 2023; Revised October 11, 2023; Accepted November 04, 2023.

1 January 2019 in Neuropsychiatria i Neuropsychologia
Verified
Journal Article
Closed access
CCCHANDRASEKHAR CHANDA
CHANDRASEKHAR CHANDA
SSSobhitha Surepalli
Sobhitha Surepalli
Dopaminergic signalling is crucial for a variety of brain functions, and abnormal dopamine regulation leads to neuropsychiatric disorders. Dopamine (DA) receptors are members of the G protein-coupled receptors (GPCRs) superfamily, with seven transmembrane spanning domains. DA, upon release from pre-synaptic neurons, activates dopamine receptor subtypes D1 to D5 and induces G alpha s/olf- and G alpha i/o-mediated intracellular signalling. Defects in DA signalling cause either over-activation or dysfunction of DA regulation, leading to major psychiatric and neurological disorders, including Parkinson's, schizophrenia, attention deficit with hyperactivity disorder, and bipolar disorder. Molecules that act as antagonists/agonists on D2/D3 receptors have been used clinically to treat many neuropsychiatric and neurodegenerative disorders. Most of the anti-psychotic drugs in use are primarily based on D2 receptor antagonism and serotonin receptor antagonism. However, antipsychotic drugs were developed 50 years ago, and the efficacy of these drugs has not been refined/upgraded very much. Thus, there is a great need to develop novel therapeutic strategies in designing/discovering a newer class of drugs. This can be achieved by having a better understanding about DA regulation and dopaminergic signalling in neuropsychiatric disorders. The in silico approach can be a tool for studying DA receptors and other protein targets involved in dopaminergic signalling. Utilising the existing knowledge on DA signalling in combination with various in silico approaches can be helpful in designing new chemical entities (NCEs). This review focuses on receptor functioning and dopaminergic signalling in major neuropsychological disorder, current therapeutic strategies, and future perspectives.